Responses
Clinical/translational cancer immunotherapy
Original research
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
